Top

Published in:

01-08-2007 | Imagers in Neuron-Oncology Clinical-Patient Studies

Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report

Authors: Abdullah Altintas, Timucin Cil, Ilhan Kilinc, Muhammet Ali Kaplan, Orhan Ayyildiz

Published in: Journal of Neuro-Oncology | Issue 1/2007

Summary

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a reciprocal translocation between chromosomes 9 and 22. Imatinib mesylate is a potent and selective inhibitory of the BCR/ABL tyrosine kinase. Imatinib is a first choice of treatment of chronic phase CML. It has also shown activity in patients with CML in accelerated or blastic phases. However, the penetration of the drug and its active metabolites into the central nervous system (CNS) is poor. Therefore, the CNS is sanctuary site for malignant cells in patients treated with imatinib. Herein, we report a patient with CML in accelerated phase that developed central nervous system disease while on imatinib mesylate therapy.

Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330–1340PubMedCrossRef

Deininger MW, Goldman JM, Melo JW (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343–3356PubMed

Kantarjian HM, Keating MJ, Talpaz M et al (1987) Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med 83:445–454PubMedCrossRef

Cervantes F, Rozman M, Rosell J, Urbano-Ispizua A, Montserrat E, Rozman C (1990) A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukemia. Br J Haematol 76:27–32PubMed

Nadal E, Olavarria E (2004) Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukemia and other malignancies. J Clin Pract 58:511–516CrossRef

Saikia TK, Dhabhar B, Iyer RS et al (1993) High incidence of meningeal leukemia in lymphoid blast crisis of chronic myeloid leukemia. Am J Hematol 43:10–13PubMedCrossRef

Naito K, Mori T, Miyazaki K, Tsukada Y, Ikeda Y, Okamato S (2003) Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (STI571). Intern Med 42:740–742PubMed

Rytting M, Wierda WG (2004) Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy. Leuk Lymphoma 45:1623–1626PubMedCrossRef

Pfeifer H, Wassmann B, Hofmann WK et al (2003) Risk and prognosis of central nervous system leukemia with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 9:4674–4681PubMed

10.

Talpaz M, Silver RT, Druker BJ et al (2002) Imatinib induces durable hematologic andcytogenetic responses in patients with accelerated phase chronic myeloid leukemia: result of phase 2 study. Blood 99:1928–1937PubMedCrossRef

11.

Bornhauser M, Jenke A, Freiberg-Richter J et al (2004) CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol 83:401–402PubMedCrossRef

12.

Dai H, Marbach P, Lemaire M, Hayes M, Elmquist W (2003) Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 304:1085–1092PubMedCrossRef

13.

Takayama N, Sato N, O’Brien SG, Ikeda Y, Okamoto SI (2002) Imatinib mesylate has a limited activity against the central nervous system involvement of Philadelphia-chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 119:106–108PubMedCrossRef

Title: Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report
Authors: Abdullah Altintas
Timucin Cil
Ilhan Kilinc
Muhammet Ali Kaplan
Orhan Ayyildiz
Publication date: 01-08-2007
Publisher: Kluwer Academic Publishers-Plenum Publishers
Published in: Journal of Neuro-Oncology / Issue 1/2007
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-007-9352-0

At a glance: The STEP trials

Springer Medicine

Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report

Summary

At a glance: The STEP trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 1/2007

Intracranial solitary juvenile xanthogranuloma successfully treated with stereotactic radiosurgery

Stereotactic radiosurgery for atypical and anaplastic meningiomas

Long-term follow-up results of postoperative radiation therapy for Cushing’s disease

Breast cancer leptomeningeal metastasis—the role of multimodality treatment

Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury

Embryonal tumor with abundant neuropil and true rosettes (ETANTR): report of a case with prominent neurocytic differentiation